{
    "nctId": "NCT00764036",
    "briefTitle": "Study of Artesunate in Metastatic Breast Cancer",
    "officialTitle": "Prospective Open Uncontrolled Phase I Study of Compatibility, Safety&Pharmacokinetics of Artesunate, a Semisynthetic Derivative of Artemisinin From the Chinese Herb Artemisia Annua in Patients With Metastatic/Locally Advanced Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Metastatic Breast Cancer, Locally Advanced Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "N/A",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 23,
    "primaryOutcomeMeasure": "Dose limiting adverse events with possible, probable or definite relation with the respective dose level of the add-on therapy",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients with histologically or cytologically confirmed breast cancer\n* Distant metastases or locally advanced breast cancer\n* Age \u2265 18 years\n* ECOG performance \u2264 2\n* Life expectancy of at least 6 months\n* Written informed consent\n* individual standard therapy according to guidelines\n* Oral intake of trial medication possible\n* Compliance with study procedures\n* Women of childbearing potential: negative pregnancy test before start of medication\n* Use of a highly effective method of birth control during intake of add-on therapy for women of childbearing potential being sexually active\n\nInclusion Criteria for Extended Treatment Phase:\n\n* Participant of the phase I study ARTIC M33/2 who had tolerated the study medication for 4\u00b11 weeks without clinically relvant adverse events or after improvement to \u2264 grade 2\n* Participant of the phase I study ARTIC M33/2 with possible benefit by continuation or restart of the add-on therapy after a next progression according to current scientific knowledge\n* Written informed consent for extended treatment phase\n* Consent of the responsible oncologist\n* Compliance for further intake and follow-up expected\n\nInclusion Criteria for Individual Compassionate Use:\n\n* Participant of the phase I study ARTIC M33/2\n* Available standard therapies have minimal or only short activity or intolerable side effects\n* Written informed consent for compassionate use\n* Consent of the responsible oncologist\n\nExclusion Criteria:\n\n* Allergy to artesunate or to other artemisinin derivatives\n* Concurrent conditions interfering with patient safety\n* Communication problems\n* Concurrent participation in another clinical trial or 4 weeks prior to recruitment\n* Participation in a clinical trial with an unapproved drug 6 months prior to recruitment\n* Sinus bradycardia, bradyarrhythmia\n* AV-Block II\u00b0 and III\u00b0\n* QTc \\> 500 msec\n* Previously known long QT-syndrome\n* Concurrent intake of a medication with clinically relevant neurotoxicity or during 30 days prior to recruitment\n* Relevant neurological symptoms which might complicate the evaluation of the compatibility of the IMPD (f. e. cerebral metastases) or might be subject to worsening during intake of the IMPD\n* Radiotherapy 2 weeks prior of the intake of the IMPD\n* Concurrent intake of supplements or any other medication with unapproved efficacy f.e. vitamins, minerals or others (OTC)\n* Pregnancy and lactation\n* Ineffective mode of contraception in women of childbearing potential\n\nExclusion Criteria for Extended Treatment Phase:\n\n* Clinically relevant adverse Events during the first 4 weeks of intake of study medication possibly, probably or definitely related to the study medication\n* Intolerable health risks by continuation re-exposition with the study medication\n* Continuation or re-exposition is medically not acceptable after consultation of physicians responsible for their standard therapy\n\nExclusion Criteria for Individual Compassionate Use:\n\n- Intolerable health risks by re-exposition with the study medication",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}